So cardiovascular research is one of the most important frontiers of medicine. Cardiovascular disease, in the western world, is one of the most significant health challenges and our customers are the researchers that are solving those issues. How do we create better treatments for better care in a very significant, essentially a, health crisis.
One of the most important challenges is translating from bench models to clinical care. And one of the biggest hurdles has been the model systems we use; rat and mouse doesn’t always translate well to human physiology. The Cardiac Slice System fills an important niche within that space. Isolating cardiomyocytes from human tissue is very difficult and they tend to be unreliable as a model system. But cardiac slices prepared from human tissue are very robust. What that means is that if you have a perturbation, some kind of compound or drug treatment that you are looking to test rather than test in rat or mouse, rather than testing IPSC derived cardiomyocytes, you can test in primary human tissue, if you are fortunate enough to have that tissue available to you; it is a reliable model system that gives you very high content data. And that allows you to interrogate what that compound does, not just in the bench setting, but how it might translate to the clinical setting.